Betaxolol
- Generic Name
- Betaxolol
- Brand Names
- Betoptic, Betoptic Pilo, Betoptic S
- Drug Type
- Small Molecule
- Chemical Formula
- C18H29NO3
- CAS Number
- 63659-18-7
- Unique Ingredient Identifier
- O0ZR1R6RZ2
- Background
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
- Indication
For the management of hypertension.
- Associated Conditions
- Hypertension, Increased Intra Ocular Pressure (IOP)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Primary Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT02617459
- Locations
- 🇨🇳
Zhongshan ophthalmic center, Sun Yat-sen University, Guangzhou, Guangdong, China
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
Phase 1
Completed
- Conditions
- Development of Side Effects From Betaxolol
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Smith-Kettlewell Eye Research Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01660620
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 105
- Registration Number
- NCT00061542
- Locations
- 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States
Early Manifest Glaucoma Trial (EMGT)
Phase 3
- Conditions
- Open-Angle Glaucoma
- First Posted Date
- 1999-09-24
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Eye Institute (NEI)
- Registration Number
- NCT00000132
- Locations
- 🇸🇪
Department of Ophthalmology, Malmo University Hospital, University of Lund, Malmo, Sweden
🇸🇪Department of Ophthalmology, Helsingborg Hospital, Helsingborg, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath